Purpose To evaluate the multifocal electroretinography (mfERG) changes in patients on ethambutol therapy. Methods A cross-sectional observational study of 17 visually asymptomatic patients receiving antituberculosis therapy with ethambutol. Patients underwent complete ophthalmic examination and mfERG recordings. The first-order mfERG N1 and P1 response amplitudes and implicit times of six concentric rings were analysed and compared with 17 normal age-similar controls. Correlation analyses were performed between the patients' mfERG parameters with parameters of ethambutol usage (daily dose of ethambutol per body weight, duration of ethambutol therapy, cumulative dose of ethambutol, and cumulative dose of ethambutol per body weight). Results The mean duration of ethambutol therapy was 3.6 months (range: 2-9 months) and the mean daily dose per body weight was 13.2 mg/kg/day. Analysis of response amplitude measures showed no significant difference in the mfERG N1 and P1 response amplitudes between the ethambutol and control groups at all ring eccentricities (P40.05). For implicit times, there were significant delays in the mfERG P1 implicit times of rings 4-6 in the ethambutol group compared with controls (P ¼ 0.012 to P ¼ 0.041). Correlation analyses showed no significant correlation between the mfERG and ethambutol parameters (P40.05). Conclusions The mfERG findings suggested that visually asymptomatic patients receiving ethambutol therapy might have localized mild electrophysiological changes involving the peripheral macula. These changes might be related to localized alteration of metabolism or physiological changes associated with ethambutol therapy.
Introduction
Ethambutol is an effective drug in the first-line treatment of tuberculosis but its use is known to be associated with ocular toxicity. 1 Toxic optic neuropathy is the most important ocular side effect and the incidence is related to the dosage and duration of ethambutol therapy. 2, 3 The incidence of ocular toxicity has been reported to be as high as 6% in patients receiving ethambutol of more than 15-25 mg/kg/day. 3, 4 Ethambutol-associated optic neuropathy can be classified according to the visual field defect as central and peripheral types. The central type involves maculopapillary bundle and results in decreased visual acuity, centrocecal scotoma, and impairment in blue-yellow colour vision, whereas the peripheral type causes peripheral visual field constriction and red-green dyschromatopsia. 5 In additiona to optic nerve toxicity, studies have also showed that ethambutol might also be toxic at the level of the retina. [6] [7] [8] [9] Multifocal electroretinography (mfERG) is an investigational tool, which allows the stimulation and recording of localized retinal responses from the macula topographically. 10, 11 Case reports have shown that mfERG can be used to detect the retinal functional abnormalities in patients with visual loss associated with ethambutol therapy. [12] [13] [14] To further evaluate the mfERG changes in patients taking ethambutol, we performed a study using mfERG to assess the retinal functional changes in visually asymptomatic patients receiving ethambutol therapy. We postulate that ethambutol might result in localized impairment of retinal function even in these visually asymptomatic patients.
Materials and methods

Subjects
This was a cross-sectional observational study carried out at the Department of Ophthalmology and Visual Sciences, the Chinese University of Hong Kong. Seventeen patients younger than 60 years of age receiving antituberculosis therapy with oral ethambutol were prospectively recruited. All patients were visually asymptomatic with visual acuity of 20/30 or better and were able to cooperate for mfERG recordings. They also had normal colour vision, normal visual field on Humphrey 24-2 automated visual field testing, and normal fundus examination. Patients with myopia of more than 6 D or any other concomitant eye diseases, such as glaucoma or diabetic retinopathy, were excluded. To prevent the potential influence of media opacity, such as cataract, in affecting the results, patients older than 60 years were excluded from the study. Informed consent was obtained in all patients and the study was approved by an institutional review board.
MfERG testing technique
MfERG recordings were performed using the VERIS 4.8 clinic system (Electro-Diagnostic Imaging, San Mateo, CA, USA) with reference to the ISCEV guidelines. 15, 16 Multiple retinal areas were stimulated using a stimulus array of 103 hexagons with a binary m-sequence length of 2 14 . The 103 hexagons were scaled by a stretch factor of 10.46, and the overall stimulus pattern subtended an angle of approximately 251 on either side of fixation. The stimulus luminance was 200 cd/m 2 for the bright flashes and 1 cd/m 2 for the dark flashes. The stimulus was displayed using a 21-inch black and white monochrome cathode ray tube monitor at a frame rate of 75 Hz. Before mfERG recording, patients' pupils were dilated using topical 0.5% tropicamide and 0.5% phenylephrine eye drops (Mydrin-P, Santen, Osaka, Japan), and all subjects were light adapted in room light for 15 min before testing. Recordings were divided into 16 segments and performed monocularly using Burian-Allen bipolar contact lens electrodes (Hansen Ophthalmic Laboratories, Iowa City, IA, USA). Topical anaesthesia with 0.5% proparacaine hydrochloride eye drops (Alcaine, Alcon, Forth Worth, TX, USA) was installed before the recording. Room lights were on throughout the recordings and the position of the patients' pupil was monitored using a refractor/camera system. Any segments with blinking, large eye movements, or fixation losses were discarded and recorded again. Retinal signals were filtered with low-and high-frequency cutoffs of 10 and 300 Hz, respectively, and amplified with a gain of 100 000.
Analysis of mfERG
The first-order kernel of the mfERG responses was analysed. Individual mfERG responses for the 103 hexagons were grouped into six concentric rings centred on the fovea for analysis. The response amplitudes and implicit times of the first negative peak (N1) and the first positive peak (P1) of each individual ring were then measured. The N1 response amplitude was measured from the starting baseline to the base of the N1 trough and the P1 response amplitude from the N1 trough to the P1 peak. The N1 and P1 implicit times were measured from the stimulus onset to the N1 trough and P1 peak, respectively.
Statistical analysis
The mean first-order mfERG N1 and P1 response amplitudes and implicit times of the six concentric rings of the ethambutol group were compared with a normal control group of volunteers using the non-parametric Mann-Whitney U-test. Non-parametric Spearman's correlation analyses were also carried out to determine any potential correlations between the mfERG response amplitudes and implicit times of various rings and the ethambutol therapy parameters. These included the daily dose per body weight, the cumulative dose, the treatment duration, and the cumulative dose per body weight. Statistical analyses were carried out using SPSS 11.5, and a P-value of 0.05 was considered as statistically significant.
Results
Patients' demographics
Seventeen patients receiving ethambutol therapy were included in the study and only the data from the left eye were used for analysis. There were six male subjects and 11 female subjects. A total of 17 eyes of 17 age-similar control subjects were used as the control group. The mean ± SD age of the ethambutol patients was 49.5 ± 8.1 years (range: 35-59 years) and the mean ± SD age of the control subjects was 46.9 ± 6.5 years (range: 38-58 years) (two-tailed t-test, P ¼ 0.16 compared with ethambutol group). The mean duration of ethambutol mfERG in ethambutol patients TYY Lai et al treatment was 3.6 months (range: 2-9 months) and the mean daily dose per body weight was 13.2 mg/kg/day (range: 6.9-25.5 mg/kg/day). Fourteen patients received antituberculosis therapy for pulmonary tuberculosis, two received treatment for lymph node tuberculosis infection, and one patient had treatment for vertebral tuberculosis. The demographic details of the patients are listed in Table 1 .
Changes in mfERG response amplitudes 
Changes in mfERG implicit times
The N1 and P1 implicit times of the ethambutol and control groups are displayed in Figure 2 . Each round dot represents the mfERG implicit time value of the individual eyes for N1 (Figure 2a ) and P1 (Figure 2b) , with the boxes showing the 25 and 75% range. The error bars represent the minimum-to-maximum values excluding the outliers. Analyses showed no significant differences in the N1 implicit times of rings 1-6 and in the P1 implicit times of rings 1-3 between the ethambutol and the control groups (P40.05). For the mean P1 implicit times of rings 4-6, significant delays were observed in patients receiving ethambutol compared with controls (P ¼ 0.012-0.041).
Correlation analyses
Correlation analyses showed no significant correlations between the mfERG N1 and P1 response amplitudes and implicit times of all ring eccentricities with the ethambutol treatment parameters including daily dose per body weight of ethambutol, duration of ethambutol therapy, the cumulative dose of ethambutol therapy, and the cumulative dose of ethambutol per body weight (P40.05).
Discussion
Although visual loss associated with ethambutol is classically described as an optic neuropathy, various clinical and electrophysiological studies have shown that ethambutol might be toxic at various retinal cell layers. 17 In a systematic review performed by Vistamehr et al, 20 These reactions appeared to be mediated by zinc and were reversible after exposure to ethambutol was removed. Studies using optical coherence tomography have also shown that ethambutol therapy is associated with reduction in the retinal nerve fibre layer thickness, suggestive of retinal ganglion cell loss. 21, 22 On the basis of these evidence, it is likely that ethambutol not only affects the optic nerve but also causes retinal changes, causing a neuroretinopathy.
As the ethambutol-associated retinopathy might be limited to the macula, case reports have used the mfERG to assess the macular dysfunction in patients with visual loss associated with ethambutol therapy.
12-14 Behbehani et al 13 described the mfERG findings of four patients with visual loss associated with ethambutol and it was found that patients had significantly lower N1 amplitude In this study, we evaluated the mfERG changes in a group of visually asymptomatic patients taking ethambutol and compared the findings with a normal control group. In terms of the mfERG response amplitudes, no significant difference was found between the ethambutol and control groups. However, analysis of implicit times showed that small but statistically significant delays in P1 implicit times were observed in rings 4-6. This suggests that ethambutol use is associated with impairment in the peripheral macular function, whereas the central macular function was not affected. Earlier studies on mfERG have shown that the P1 response mainly arises from the on-bipolar and Mü ller cells, with some contributions from the retinal ganglion cells. 23, 24 These localized delays in mfERG P1 implicit times have also been observed in patients with diabetes mellitus or those using hydroxychloroquine in whom there were no visible retinal changes on clinical examination. [24] [25] [26] We postulate that the delays in P1 implicit times observed in patients using ethambutol probably reflect physiological stress or localized alteration of cellular metabolism associated with ethambutol therapy. The exact cause for the delays in mfERG P1 implicit times in the ethambutol patients remained uncertain. Correlation analyses failed to show any correlation between the mfERG parameters with the daily dose per body weight, the duration of ethambutol therapy, the total cumulative dose of ethambutol, or the total cumulative dose of ethambutol per body weight on the mfERG parameters. The lack of correlation between the mfERG findings and the ethambutol parameters might be due to the small sample size in the study and further studies are required to determine the underlying mechanisms in causing the mfERG changes.
The main limitation of this study was its cross-sectional nature, and therefore we could not determine any possible serial changes in mfERG parameters associated with ethambutol therapy. Secondly, the magnitude of the implicit time changes observed was small in the region of around 1 ms, and this small delay in implicit time might not be of clinical significance. Thirdly, the mfERG responses were grouped for analysis and localized impairment might be missed without analysing the responses from individual hexagons. Moreover, the small sample size in this study might have led to negative results in the analysis for the response amplitudes. Another reason for the lack of significant difference in mfERG response amplitudes might be due to the relatively short duration of ethambutol therapy in many patients. Fourthly, patients were also receiving other antituberculosis drugs including isoniazid and the additive toxic effects may also result in ocular toxicity, and therefore the contribution of other drugs in causing the mfERG changes observed could not be excluded. Lastly, there was a lack of anatomical correlation with the mfERG findings, such as optical coherence tomography, to document the retinal nerve fibre thickness, and only Humphrey 24-2 visual field testing was performed, which might have missed some central or cecocentral scotomas in the patients.
In conclusion, our findings suggested that slight delays in mfERG P1 implicit times of the peripheral macula may occur in patients on ethambutol therapy. Nonetheless, the other mfERG parameters were normal and there was no correlation between the mfERG P1 implicit time and the dosage or length of ethambutol use. Therefore, even though there was evidence suggesting that the drug is capable of producing retinal damage, it is difficult to base on our data to confirm that ethambutol resulted in significant macular dysfunction in visually asymptomatic patients at the doses specified. Further studies with larger sample sizes will be required to verify whether the mfERG changes observed were ethambutolrelated and to compensate the potential variability of mfERG amplitudes and implicit times. Longitudinal studies will also be beneficial to assess the clinical significance of the mfERG change in patients taking ethambutol and to determine whether mfERG is useful in predicting the development of ethambutol-associated neuroretinopathy.
